

**Election of Species**

In accordance with MPEP 803.02 Applicants hereby provisionally elect the species identified by Example 154: 2-{5-[3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-phenyl]-[1,3,4]oxadiazol-2-ylamino}-propane-1,3-diol for the purposes of examination only.

Applicants believe that Claims 1 and 2 read on this elected species.

**Conclusion**

Applicants believe all claims are now in condition for allowance. Should there be any issues that have not been addressed to the Examiner's satisfaction, Applicants invite the Examiner to contact the undersigned attorney.

Applicants do not believe any fees are due in connection with this response. If any fees are due in connection with this response, please charge such fees to Deposit Account No. 500329.

Respectfully submitted,

Date: November 4, 2005

Galina Yakovleva  
Galina M. Yakovleva, Ph.D.  
Attorney For Applicants  
Registration No. 47,192

Agouron Pharmaceuticals, Inc./A Pfizer Company  
Patent Department  
10777 Science Center Drive  
San Diego, California 92121  
Phone: (858) 622-6095  
Fax: (858) 678-8233